We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Miltefosine for Mucosal Leishmaniasis

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00373776
First Posted: September 8, 2006
Last Update Posted: September 8, 2006
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
AB Foundation
September 7, 2006
September 8, 2006
September 8, 2006
April 2004
Not Provided
Efficacy
Same as current
No Changes Posted
toxicity
Same as current
Not Provided
Not Provided
 
Miltefosine for Mucosal Leishmaniasis
Not Provided
This trial will study miltefosine as a treatment for mucosal leishmaniasis.
Treat bolivian mucosal leishmaniasis with miltefosine.
Interventional
Phase 1
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Leishmaniasis
Drug: miltefosine 2.5 mg/kg/day for 28 days
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
75
May 2006
Not Provided

Inclusion Criteria:

  • Mucosal leishmaniasis

Exclusion Criteria:

  • Abnormal liver function tests (LFT)
  • Abnormal kidney function test
  • Concomitant diseases
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Bolivia
 
 
NCT00373776
04--01
Not Provided
Not Provided
Not Provided
Not Provided
AB Foundation
Not Provided
Principal Investigator: Jaime soto, MD CIBIC
AB Foundation
September 2006

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP